In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Hepion Pharmaceuticals Inc.

www.contravir.com

Latest From Hepion Pharmaceuticals Inc.

Tech Transfer Roundup: Tonix Obtains Triple-Reuptake Inhibitor For PTSD From Wayne State

TNX-1600 joins two other candidates, including Phase III TNX-102 SL, in Tonix’s PTSD portfolio. CureVac and Yale partner on mRNA therapies for pulmonary disease.

Commercial Deals

Pipeline Watch: Phase III Progress With BL-8040, Recorlev And Estelle

Pipeline Watch is a weekly snapshot of selected late-stage clinical trial events announced by pharmaceutical and biotech companies at medical and industry conferences, in financial and company presentations, and in company releases and statements.

 

Pipeline Watch Approvals

In Hep B, Functional Cure Likely Means Two-Part Combination Process

While current HBV drugs work well to suppress the virus, combination success in HIV and HCV is leading biopharmas to seek a multi-part approach to suppressing and clearing the virus, with limited-term therapy.

Infectious Diseases Clinical Trials

Deals Shaping The Medical Industry, May 2017

Derived from Strategic Transactions, Informa’s premium source for tracking life sciences deal activity, the Deal-making column is a survey of recent health care transactions listed by relevant industry segment – In Vitro Diagnostics, Medical Devices, and Pharmaceuticals – and then categorized by type – Acquisition, Alliance, or Financing. This month’s column covers deals announced in April 2017.

Deals BioPharmaceutical
See All

Company Information

  • Industry
  • Pharmaceuticals
  • Therapeutic Areas
  • Hepatic (Liver)
  • Infectious & Viral Diseases
  • Alias(es)
  • ContraVir Pharmaceuticals Inc.
  • Ownership
  • Public
  • Headquarters
  • Worldwide
    • North America
      • USA
  • Parent & Subsidiaries
  • Hepion Pharmaceuticals Inc.
  • Senior Management
  • Robert Foster, PhD, CEO
    John Cavan, CFO
  • Contact Info
  • Hepion Pharmaceuticals Inc.
    Phone: (732) 902-4000
    399 Thornall St., First Fl.
    Edison, NJ 08837
    USA
Advertisement
Advertisement
UsernamePublicRestriction

Register